Celgene Corporation (CELG)'s Fastest-Growing Drug
What's the fastest growing drug in Celgene Corporation (NASDAQ:CELG)'s portfolio? It isn't Revlimid, Vidaza, or Abraxane.
Onyx Pharmaceuticals Inc (ONXX)
Market is closed
News
- First
- << Previous
- 81 - 86
This Just In: Upgrades and Downgrades - Dendreon Corporation (DNDN) and More
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you whether those bigwigs actually...
Can Johnson & Johnson (JNJ) Hold Its Ground in the Multiple Myeloma Market?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic compounds.
What's Next for Sarepta Therapeutics Inc (SRPT)?
What's next for Sarepta Therapeutics Inc (NASDAQ:SRPT) ? After announcing encouraging results last October from a phase 2b study of eteplirsen targeting treatment of Duchenne muscular dystrophy, or DMD...
More Good News for Celgene Corporation (CELG)
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene Corporation (NASDAQ:CELG)'s Pomalyst in treating patients with multiple myeloma.
Celgene Corporation (CELG): Still Revving Up With Revlimid
What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months.
- First
- << Previous
- 81 - 86
Billionaire Hedge Funds
